Ask a Question

User zephyrcub2

Member for: 3 days (since Jun 28)
Type: Registered user
Full name:
Location:
Website: https://www.selleckchem.com/products/ZM-447439.html
About: Anlotinib joined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs following several lines treatment method: An open-label, dosage escalation and also expansion study.

Activity by zephyrcub2

Score: 100 points (ranked #601)
Questions: 0
Answers: 0
Comments: 0

Wall for zephyrcub2

Please log in or register to post on this wall.
Snow Theme by Q2A Market
Powered by Question2Answer
...